Hypothesis-Generating Research and Predictive Medicine. Sanford Imagenetics Genomic Medicine Symposium October 10, 2014

Size: px
Start display at page:

Download "Hypothesis-Generating Research and Predictive Medicine. Sanford Imagenetics Genomic Medicine Symposium October 10, 2014"

Transcription

1 Hypothesis-Generating Research and Predictive Medicine Sanford Imagenetics Genomic Medicine Symposium October 10, 2014

2 Outline Research Hypothesis-generating v. hypothesis-testing Clinical care Diagnostic v. predictive Incidental findings & predictive medicine

3 Current Clinical Research Paradigm Gather background information Formulate hypothesis Phenotype subjects Apply a biologic assay to subject to test Interpret data, refine, and extend hypothesis

4 Hypothesis-Generating Research Assemble a cohort of subjects Generate large-scale dataset Parse genomic data for patterns, perturbations, etc. Hypothesis for how the omic attribute affects the subject Test the hypothesis with clinical research

5 ClinSeq Cohort Enrolled >1,000 subjects Primary phenotype atherosclerosis Consented for Full sequencing Downstream phenotyping - any >950 exomes Mb exome captures > 5 trillion bp >2,500,000 variants ~300,000 nonsense, frameshift, splice site, and non-synonymous Biesecker et al, Genome Res :

6 Combined Malonic & MethylMalonic Acidemia (CMAMMA) Organic acidosis, childhood onset with metabolic decompensation, CNS infarcts, coma Autosomal recessive Exome sequenced a single nuclear trio Filters 12 genes One (ACSF3) with mitochondrial leader 7 additional patients 6/7 with 2 rare variants Functional data, complementation Sloan et al. Nat Genet :

7 TYPE # TYPED HomRef HetRef HomNRef REF VAR AA# Damaging dbsnp SPL NonSyn L P 2-4 NonSyn R W 10 0 NonSyn A P 17-5 rs (g,c) FS NonSyn G S 64-7 NonSyn P A NonSyn P S NonSyn P L NonSyn R W NonSyn D N NonSyn R L NonSyn I V NonSyn E K NonSyn V M rs (g,a) NonSyn R P NonSyn V M NonSyn R Q NonSyn R W NonSyn A T Stop W * NonSyn R W

8 TYPE # TYPED HomRef HetRef HomNRef REF VAR AA# Damaging dbsnp SPL NonSyn L P 2-4 NonSyn R W 10 0 NonSyn A P 17-5 rs (g,c) FS NonSyn G S 64-7 NonSyn P A NonSyn P S NonSyn P L NonSyn R W NonSyn D N NonSyn R L NonSyn I V NonSyn E K NonSyn V M rs (g,a) NonSyn R P NonSyn V M NonSyn R Q NonSyn R W NonSyn A T Stop W * NonSyn R W

9 Clinical Evaluation 66 yo female Recent history 4 car accidents, memory difficulties, incontinence Serum and urine analysis MMA plasma 48 um (100x ULN), urine 70x ULN MA plasma 11 um (nl undetectable) Cranial MRI Multiple small high intensity signals, c/w infarcts

10 Conclusions Proof of causation for ACSF3 mutations Current understanding of phenotypic spectrum wrong Modifiers matter

11 Conclusions Hypothesis testing model leads to circular reasoning Unbiased ascertainment of phenotypes essential to knowing full spectrum Iterative clinical research essential requires thorough consent & motivated cohort

12 Predictive Medicine What is it? Predictive medicine, Personalized medicine, Precision medicine Precisely applying prevention and treatments Those who have highest risks of disease, complications, particular prognosis Maximize efficacy, minimize side effects

13 Current Clinical Practice Paradigm Chief complaint & history Physical examination Formulate differential diagnosis Select & apply clinical test(s) to patient Interpret result(s), refine differential, diagnose Treat

14

15 Predictive Medicine Model Basic patient intake & consent Generate large-scale dataset Parse genomic data for patterns, perturbations, etc. Predict how the omic attribute affects the subject Test the hypothesis with clinical evaluation

16 Health Predictions Need ability to assay an attribute of patient that defines occult disease or future risk Physical signs on health maintenance visit Newborn screening

17 Scientific Predictions Prediction is very difficult, especially if it's about the future. Niels Bohr

18 Scientific Predictions Prediction is very difficult, especially if it's about the future. Niels Bohr Occurrences in this domain are beyond the reach of exact prediction because of the variety of factors in operation, not because of any lack of order in nature. Albert Einstein

19 Health Predictions Need ability to assay an attribute of patient that defines occult disease or future risk Physical signs on health maintenance visit Newborn screening Why not for all heritable disorders? Need assay to broadly assess risks Until recently it was technically impossible

20 Incidental Findings in ClinSeq Key objection Unknown penetrance of variants outside of positive family history context A phenotype-centric view Cardiomyopathy/dysrhythmia A genome-wide approach All null variants

21

22 Evaluate This Question Cardiomyopathy/dysrhythmias 870 exomes Evaluate 63 known genes Set high thresholds for pathogenicity

23 Cardiomyopathy & Dysrhythmias MYH7 IVS8+1G>A Reinterpretation MRI > L ventricular non-compaction MYBPC3 p.arg495gln Concentric L ventricular hypertrophy MYBPC3 p.gly490arg Asymmetric septal hypertrophy

24 Cardiomyopathy & Dysrhythmias MYH7 IVS8+1G>A Reinterpretation MRI > L ventricular non-compaction MYBPC3 p.arg495gln Concentric L ventricular hypertrophy MYBPC3 p.gly490arg Asymmetric septal hypertrophy All abnormal imaging and family history

25 Cardiomyopathy & Dysrhythmias MYH7 IVS8+1G>A Reinterpretation MRI > L ventricular non-compaction MYBPC3 p.arg495gln Concentric L ventricular hypertrophy MYBPC3 p.gly490arg Asymmetric septal hypertrophy All abnormal imaging and family history Similar results with dysrhythmias (3/3)

26 Conclusions You can identify pathogenic variants from genomic data in unselected patients Need to use high thresholds for pathogenicity Current concerns may lead us to be too conservative Our positive prediction value for cardiac disease is 100%

27 A Genomic View How generalizable is this and how often can you make predictions from exomes? Search 950 exomes for all null variants Nonsense, frameshift, splice Known disease causing genes Haploinsufficiency genes Actual disease (not traits)

28 Null Variants - Positives (32) BRCA1 (2) BRCA2 (4) FLCN (2) HOXD13 KCNQ4 KRT16 LDLR (7) MSH6 PKD1 PMPP PMS2 PPARG PROS1 SALL4 SFTPC SGCE SLC4A1 (2) TGIF1

29 Null Variants - Positives KCNQ4 c.1725del p.ile576serfsx40 Mod-Severe S-N hearing loss PPARG p.glu499argfsx12 Familial partial lipodystrophy HOXD13 c.820c>t p.arg274x Limb anomalies FLCN c g>a p.trp306x Biopsy positive

30 Null Variants Negatives (32) ATP2C1 BRCA1 (2) BRCA2 COL10A1 (3) DMD DSG1 EPHA2 GLI2 GLI3 GNAS HSPB1 MSH6 MYH6 MYOC (4) OFD1 PMS2 (2) PRKCSH (2) RP1 RUNX1 SDHC SMAD3 TGIF1 TRPC6 PAX3

31 Null Variants - Negatives ARID1B Coffin-Siris syndrome / ID c.1762g>t, p.glu588x GLI3 Greig cephalopolysyndactyly syndrome c.45g>t, p.lys15x MYOC Open angle glaucoma c.1102c>t, p.q368x

32 Null Variant Screen Why negatives? Variant in far 3 of gene Truncated protein > hypomorphic Variant in far 5 of gene Alternative translation initiation Non-obligate exon Skipping of stop Incorrect gene model Incomplete penetrance / variable expressivity

33 Null Variant Screen About 50% yield of disease 2-3% of participants Most undiagnosed Probably underestimate Not all such genes known Subset of pathogenic mutations Conservative phenotyping

34 Bayesian Reasoning A major criticism of Precision Medicine If prior probability 1/50,000, 99.9% reliable test yields ~2% true positives, ~98% false positives Prior probability incorrect If using a genomic screen, then prior is sum of frequencies of ALL detectable disorders Our estimate suggests this is in 5-10% range

35 An Incidental Finding 56 yo man in heart disease sequencing study Fam Hx: 59 yo sister with ductal carcinoma No genetic testing Proband: BRCA1 c.68_69delag, p.glu23valfsx17 Shared with sister Tested, positive Underwent hysterectomy and ovariectomy

36 Serous Tubal Intraepithelial Carcinoma H&E BRCA1 p53 A B C D E F

37 An Incidental Finding 56 yo man in heart disease sequencing study Fam Hx: 59 yo sister w DCIS No genetic testing Proband: BRCA1 c.68_69delag, p.glu23valfsx17 Shared with sister Tested, positive Underwent hysterectomy and ovariectomy Back to OR for nodes & peritoneal wash Negative

38 Predictive Medicine Arguments Can t interpret most variants Some variants highly predictive

39 Predictive Medicine Arguments Can t interpret most variants Some variants highly predictive Don t know penetrance Crude estimates useful

40 Predictive Medicine Arguments Can t interpret most variants Some variants highly predictive Don t know penetrance Crude estimates useful No data on clinical utility Medical common sense works

41 Predictive Medicine Arguments Can t interpret most variants Some variants highly predictive Don t know penetrance Crude estimates useful No data on clinical utility Medical common sense works Why all the fuss?

42

43 Genetic Exceptionalism Genetics is conceptually distinct Genetics practice distinct Geneticists more kind to patients

44

45 History

46 Diagnostic-Therapeutic Gap

47 Reproductive Genetics

48 Conclusions Hypothesis-generating clinical research now possible Can discover things that hypothesis-testing research cannot Phenotype-driven Readily extracted from exomes Yield ~2% Genomics-driven search of null variants Undiagnosed disease ~50% positive predictive value

49 Conclusions Genome & exome seq not indicated for healthy people Can be very useful for patients with rare or unexplained diseases Incidental findings = predictive medicine Predictive medicine is just medicine

50 Mainstream Medicine

51 Thanks to Katie Lewis Jennifer Johnston David Ng Steven Gonsalves Wendy Rubenstein David Cooper Peter Stenson Charles Venditti

variant led to a premature stop codon p.k316* which resulted in nonsense-mediated mrna decay. Although the exact function of the C19L1 is still

variant led to a premature stop codon p.k316* which resulted in nonsense-mediated mrna decay. Although the exact function of the C19L1 is still 157 Neurological disorders primarily affect and impair the functioning of the brain and/or neurological system. Structural, electrical or metabolic abnormalities in the brain or neurological system can

More information

Concurrent Practical Session ACMG Classification

Concurrent Practical Session ACMG Classification Variant Effect Prediction Training Course 6-8 November 2017 Prague, Czech Republic Concurrent Practical Session ACMG Classification Andreas Laner / Anna Benet-Pagès 1 Content 1. Background... 3 2. Aim

More information

CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi

CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi 2 CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE Dr. Bahar Naghavi Assistant professor of Basic Science Department, Shahid Beheshti University of Medical Sciences, Tehran,Iran 3 Introduction Over 4000

More information

Clinical utility of the functional mrna evaluation of rare genetic variants in diagnostic practice

Clinical utility of the functional mrna evaluation of rare genetic variants in diagnostic practice Clinical utility of the functional mrna evaluation of rare genetic variants in diagnostic practice Celia Duff-Farrier: STP MSc project 2017 Funding provided by the Showering Fund mrna functional evaluation

More information

Re-classification of variants: Implications from the cardiac perspective

Re-classification of variants: Implications from the cardiac perspective Re-classification of variants: Implications from the cardiac perspective Karen McGuire Oxford Medical Genetics Laboratories, Churchill Hospital, Old Road, Oxford, OX3 7LE. Re-classification New evidence

More information

Supplementary Table e1. Clinical and genetic data on the 37 participants from the WUSM

Supplementary Table e1. Clinical and genetic data on the 37 participants from the WUSM Supplementary Data Supplementary Table e1. Clinical and genetic data on the 37 participants from the WUSM cohort. Supplementary Table e2. Specificity, sensitivity and unadjusted ORs for glioma in participants

More information

Clinical Genetics in Cardiomyopathies

Clinical Genetics in Cardiomyopathies Clinical Genetics in Cardiomyopathies Γεώργιος Κ Ευθυμιάδης Αναπληρωτής Καθηγητής Καρδιολογίας ΑΠΘ No conflict of interest Genetic terms Proband: The first individual diagnosed in a family Mutation: A

More information

LMM / emerge III Network Reference Sequences October 2016 LMM / emerge III Network Consensus Actionable Gene List *ACMG56 gene

LMM / emerge III Network Reference Sequences October 2016 LMM / emerge III Network Consensus Actionable Gene List *ACMG56 gene LMM / emerge III Network Consensus Actionable Gene List *ACMG56 gene ACTA2* Exon 02-09 NM_001613.2 DSG2* Exon 01-15 NM_001943.3 ACTC1* Exon 01-06 NM_005159.4 DSP* Exon 01-24 NM_004415.2 APC* Exon 01-15

More information

Rare Variant Burden Tests. Biostatistics 666

Rare Variant Burden Tests. Biostatistics 666 Rare Variant Burden Tests Biostatistics 666 Last Lecture Analysis of Short Read Sequence Data Low pass sequencing approaches Modeling haplotype sharing between individuals allows accurate variant calls

More information

Identifying Mutations Responsible for Rare Disorders Using New Technologies

Identifying Mutations Responsible for Rare Disorders Using New Technologies Identifying Mutations Responsible for Rare Disorders Using New Technologies Jacek Majewski, Department of Human Genetics, McGill University, Montreal, QC Canada Mendelian Diseases Clear mode of inheritance

More information

Prevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D.

Prevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D. Prevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D. Hereditary Cancer Center, Peking University Cancer Hospital 1 Breast cancer

More information

Variant Detection & Interpretation in a diagnostic context. Christian Gilissen

Variant Detection & Interpretation in a diagnostic context. Christian Gilissen Variant Detection & Interpretation in a diagnostic context Christian Gilissen c.gilissen@gen.umcn.nl 28-05-2013 So far Sequencing Johan den Dunnen Marja Jakobs Ewart de Bruijn Mapping Victor Guryev Variant

More information

Merging single gene-level CNV with sequence variant interpretation following the ACMGG/AMP sequence variant guidelines

Merging single gene-level CNV with sequence variant interpretation following the ACMGG/AMP sequence variant guidelines Merging single gene-level CNV with sequence variant interpretation following the ACMGG/AMP sequence variant guidelines Tracy Brandt, Ph.D., FACMG Disclosure I am an employee of GeneDx, Inc., a wholly-owned

More information

Genetic Counselling in relation to genetic testing

Genetic Counselling in relation to genetic testing Genetic Counselling in relation to genetic testing Dr Julie Vogt Consultant Geneticist West Midlands Regional Genetics Service September 2016 Disclosures for Research Support/P.I. Employee Consultant Major

More information

Benefits and pitfalls of new genetic tests

Benefits and pitfalls of new genetic tests Benefits and pitfalls of new genetic tests Amanda Krause Division of Human Genetics, NHLS and University of the Witwatersrand Definition of Genetic Testing the analysis of human DNA, RNA, chromosomes,

More information

Introduction. Introduction

Introduction. Introduction Introduction We are leveraging genome sequencing data from The Cancer Genome Atlas (TCGA) to more accurately define mutated and stable genes and dysregulated metabolic pathways in solid tumors. These efforts

More information

Lessons from a Genomic Screening Program Mike Murray, MD Geisinger Genomic Medicine Institute

Lessons from a Genomic Screening Program Mike Murray, MD Geisinger Genomic Medicine Institute Lessons from a Genomic Screening Program Mike Murray, MD Geisinger Genomic Medicine Institute November 1 st 2017 Roundtable on Genomics and Precision Health National Academy of Science Washington DC 1

More information

Key determinants of pathogenicity

Key determinants of pathogenicity Key determinants of pathogenicity Session 6: Determining pathogenicity and genotype-phenotype correlation J. Peter van Tintelen MD PhD Clinical geneticist Academic Medical Center Amsterdam, the Netherlands

More information

Whole Exome Sequencing (WES): Questions and Answers for Providers

Whole Exome Sequencing (WES): Questions and Answers for Providers Whole Exome Sequencing (WES): Questions and Answers for Providers 1. What is Whole Exome Sequencing?... 2 2. What is the difference between Whole Exome Sequencing (WES) and Whole Exome Sequencing Plus

More information

2011 HCM Guideline Data Supplements

2011 HCM Guideline Data Supplements Data Supplement 1. Genetics Table Study Name/Author (Citation) Aim of Study Quality of life and psychological distress quality of life and in mutation psychological carriers: a crosssectional distress

More information

UAB P30 CORE A: The Hepato-Renal Fibrocystic Diseases Translational Resource

UAB P30 CORE A: The Hepato-Renal Fibrocystic Diseases Translational Resource PKD Foundation UAB P30 CORE A: The Hepato-Renal Fibrocystic Diseases Translational Resource http://www.arpkdstudies.uab.edu/ Director: Co-Director: Lisa M. Guay-Woodford, MD William E. Grizzle, MD, PhD

More information

NGS in Diagnostics: a practical example in hereditary cardiomyopathies

NGS in Diagnostics: a practical example in hereditary cardiomyopathies NGS in Diagnostics: a practical example in hereditary cardiomyopathies Patricia Norambuena University Hospital Motol, Prague. 2 nd Faculty of Medicine, Charles University VEP Course - November 6 th - 8th,

More information

Home Brewed Personalized Genomics

Home Brewed Personalized Genomics Home Brewed Personalized Genomics The Quest for Meaningful Analysis Results of a 23andMe Exome Pilot Trio of Myself, Wife, and Son February 22, 2013 Gabe Rudy, Vice President of Product Development Exome

More information

Tumor suppressor genes D R. S H O S S E I N I - A S L

Tumor suppressor genes D R. S H O S S E I N I - A S L Tumor suppressor genes 1 D R. S H O S S E I N I - A S L What is a Tumor Suppressor Gene? 2 A tumor suppressor gene is a type of cancer gene that is created by loss-of function mutations. In contrast to

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Leber congenital amaurosis OMIM number for disease 204000 Disease alternative

More information

The Deciphering Development Disorders (DDD) project: What a genomic approach can achieve

The Deciphering Development Disorders (DDD) project: What a genomic approach can achieve The Deciphering Development Disorders (DDD) project: What a genomic approach can achieve RCP ADVANCED MEDICINE, LONDON FEB 5 TH 2018 HELEN FIRTH DM FRCP DCH, SANGER INSTITUTE 3,000,000,000 bases in each

More information

Familial DilatedCardiomyopathy Georgios K Efthimiadis, MD

Familial DilatedCardiomyopathy Georgios K Efthimiadis, MD Familial DilatedCardiomyopathy Georgios K Efthimiadis, MD Dilated Cardiomyopathy Dilated LV/RV, reduced EF, in the absence of CAD valvulopathy pericardial disease Prevalence:40/100.000 persons Natural

More information

DMD Genetics: complicated, complex and critical to understand

DMD Genetics: complicated, complex and critical to understand DMD Genetics: complicated, complex and critical to understand Stanley Nelson, MD Professor of Human Genetics, Pathology and Laboratory Medicine, and Psychiatry Co Director, Center for Duchenne Muscular

More information

PERSONALIZED GENETIC REPORT CLIENT-REPORTED DATA PURPOSE OF THE X-SCREEN TEST

PERSONALIZED GENETIC REPORT CLIENT-REPORTED DATA PURPOSE OF THE X-SCREEN TEST INCLUDED IN THIS REPORT: REVIEW OF YOUR GENETIC INFORMATION RELEVANT TO ENDOMETRIOSIS PERSONAL EDUCATIONAL INFORMATION RELEVANT TO YOUR GENES INFORMATION FOR OBTAINING YOUR ENTIRE X-SCREEN DATA FILE PERSONALIZED

More information

The Genetics of Usher Syndrome

The Genetics of Usher Syndrome The Genetics of Usher Syndrome Heidi L. Rehm, PhD, FACMG Assistant Professor of Pathology, BWH and HMS Director, Laboratory for Molecular Medicine, PCPGM DNA is Highly Compacted into Chromosomes The DNA

More information

Nature Genetics: doi: /ng Supplementary Figure 1

Nature Genetics: doi: /ng Supplementary Figure 1 Supplementary Figure 1 Illustrative example of ptdt using height The expected value of a child s polygenic risk score (PRS) for a trait is the average of maternal and paternal PRS values. For example,

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISORDER/CONDITION POPULATION TRIAD Submitting laboratory: Exeter RGC Approved: Sept 2013 1. Disorder/condition

More information

JULY 21, Genetics 101: SCN1A. Katie Angione, MS CGC Certified Genetic Counselor CHCO Neurology

JULY 21, Genetics 101: SCN1A. Katie Angione, MS CGC Certified Genetic Counselor CHCO Neurology JULY 21, 2018 Genetics 101: SCN1A Katie Angione, MS CGC Certified Genetic Counselor CHCO Neurology Disclosures: I have no financial interests or relationships to disclose. Objectives 1. Review genetic

More information

Variant Classification. Author: Mike Thiesen, Golden Helix, Inc.

Variant Classification. Author: Mike Thiesen, Golden Helix, Inc. Variant Classification Author: Mike Thiesen, Golden Helix, Inc. Overview Sequencing pipelines are able to identify rare variants not found in catalogs such as dbsnp. As a result, variants in these datasets

More information

Hereditary Cardiovascular Conditions. genetic testing for undiagnosed diseases

Hereditary Cardiovascular Conditions. genetic testing for undiagnosed diseases Hereditary Cardiovascular Conditions genetic testing for undiagnosed diseases What is Hypertrophic Cardiomyopathy (HCM)? normal heart heart with hcm Extra or thick heart muscle Typically in the left ventricle

More information

MutationTaster & RegulationSpotter

MutationTaster & RegulationSpotter MutationTaster & RegulationSpotter Pathogenicity Prediction of Sequence Variants: Past, Present and Future Dr. rer. nat. Jana Marie Schwarz Klinik für Pädiatrie m. S. Neurologie Exzellenzcluster NeuroCure

More information

Clinical Genetics. Functional validation in a diagnostic context. Robert Hofstra. Leading the way in genetic issues

Clinical Genetics. Functional validation in a diagnostic context. Robert Hofstra. Leading the way in genetic issues Clinical Genetics Leading the way in genetic issues Functional validation in a diagnostic context Robert Hofstra Clinical Genetics Leading the way in genetic issues Future application of exome sequencing

More information

Atlas of Genetics and Cytogenetics in Oncology and Haematology

Atlas of Genetics and Cytogenetics in Oncology and Haematology Atlas of Genetics and Cytogenetics in Oncology and Haematology Genetic Counseling I- Introduction II- Motives for genetic counseling requests II-1. Couple before reproduction II-2. Couple at risk III-

More information

Molecular Diagnostic Laboratory 18 Sequencing St, Gene Town, ZY Tel: Fax:

Molecular Diagnostic Laboratory 18 Sequencing St, Gene Town, ZY Tel: Fax: Molecular Diagnostic Laboratory 18 Sequencing St, Gene Town, ZY 01234 Tel: 555-920-3333 Fax: 555-920-3334 www.moldxlaboratory.com Patient Name: Jane Doe Specimen type: Blood, peripheral DOB: 04/05/1990

More information

Issues arising from UKNEQAS schemes. Ottie O Brien, Northern Genetics Service, Newcastle, UK 15 th May 2014

Issues arising from UKNEQAS schemes. Ottie O Brien, Northern Genetics Service, Newcastle, UK 15 th May 2014 Issues arising from UKNEQAS schemes Ottie O Brien, Northern Genetics Service, Newcastle, UK 15 th May 2014 2013 schemes There was great variation in the way HGVS nomenclature was applied Scheme would like

More information

How many disease-causing variants in a normal person? Matthew Hurles

How many disease-causing variants in a normal person? Matthew Hurles How many disease-causing variants in a normal person? Matthew Hurles Summary What is in a genome? What is normal? Depends on age What is a disease-causing variant? Different classes of variation Final

More information

Role of next generation sequencing in clinical care

Role of next generation sequencing in clinical care Role of next generation sequencing in clinical care Anne Slavotinek Division of Genetics, Department of Pediatrics, UCSF Structure 1. Next generation technologies 2. Consent and secondary findings 3. Genetics

More information

J. Peter van Tintelen MD PhD Clinical Geneticist Amsterdam, the Netherlands

J. Peter van Tintelen MD PhD Clinical Geneticist Amsterdam, the Netherlands Inherited arrhythmia syndromes I: What you always wanted to know, but were afraid to ask: The basics of inherited arrhythmia syndromes and gene:cs J. Peter van Tintelen MD PhD Clinical Geneticist Amsterdam,

More information

Supplementary Figure 1

Supplementary Figure 1 Supplementary Figure 1 An example of the gene-term-disease network automatically generated by Phenolyzer web server for 'autism'. The largest word represents the user s input term, Autism. The pink round

More information

Classification of genetic variants in genes associated with Lynch syndrome using a clinical history weighting algorithm

Classification of genetic variants in genes associated with Lynch syndrome using a clinical history weighting algorithm Morris et al. BMC Genetics (2016) 17:99 DOI 10.1186/s12863-016-0407-0 RESEARCH ARTICLE Classification of genetic variants in genes associated with Lynch syndrome using a clinical history weighting algorithm

More information

TPMI Presents: Translational Genomics Research Update, Opportunities and Challenges

TPMI Presents: Translational Genomics Research Update, Opportunities and Challenges TPMI Presents: Translational Genomics Research Update, Opportunities and Challenges April 12, 2016 Darren D. O Rielly, Ph.D., FCCMG Director, Molecular Genetics Laboratory, Eastern Health Director, Translational

More information

Dr. Ayman Mohsen Mashi, MBBS Consultant Hematology & Blood Transfusion Department Head, Laboratory & Blood Bank King Fahad Central Hospital, Gazan,

Dr. Ayman Mohsen Mashi, MBBS Consultant Hematology & Blood Transfusion Department Head, Laboratory & Blood Bank King Fahad Central Hospital, Gazan, Dr. Ayman Mohsen Mashi, MBBS Consultant Hematology & Blood Transfusion Department Head, Laboratory & Blood Bank King Fahad Central Hospital, Gazan, KSA amashi@moh.gov.sa 24/02/2018 β-thalassemia syndromes

More information

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Epileptic encephalopathy, early infantile 4. OMIM number for disease 612164 Disease

More information

Familial and Hereditary Colon Cancer

Familial and Hereditary Colon Cancer Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of

More information

CANCER GENETICS PROVIDER SURVEY

CANCER GENETICS PROVIDER SURVEY Dear Participant, Previously you agreed to participate in an evaluation of an education program we developed for primary care providers on the topic of cancer genetics. This is an IRB-approved, CDCfunded

More information

MSI positive MSI negative

MSI positive MSI negative Pritchard et al. 2014 Supplementary Figure 1 MSI positive MSI negative Hypermutated Median: 673 Average: 659.2 Non-Hypermutated Median: 37.5 Average: 43.6 Supplementary Figure 1: Somatic Mutation Burden

More information

Reporting TP53 gene analysis results in CLL

Reporting TP53 gene analysis results in CLL Reporting TP53 gene analysis results in CLL Mutations in TP53 - From discovery to clinical practice in CLL Discovery Validation Clinical practice Variant diversity *Leroy at al, Cancer Research Review

More information

Left ventricular non-compaction: the New Cardiomyopathy on the Block

Left ventricular non-compaction: the New Cardiomyopathy on the Block Left ventricular non-compaction: the New Cardiomyopathy on the Block Aamir Jeewa MB BCh, FAAP, FRCPC Section Head, Cardiomyopathy & Heart Function Program The Hospital for Sick Children Assistant Professor

More information

CHAPTER IV RESULTS Microcephaly General description

CHAPTER IV RESULTS Microcephaly General description 47 CHAPTER IV RESULTS 4.1. Microcephaly 4.1.1. General description This study found that from a previous study of 527 individuals with MR, 48 (23 female and 25 male) unrelated individuals were identified

More information

ROLE OF MRI IN SCREENING, DIAGNOSIS AND MANAGEMENT OF BREAST CANCER. B.Zandi Professor of Radiology

ROLE OF MRI IN SCREENING, DIAGNOSIS AND MANAGEMENT OF BREAST CANCER. B.Zandi Professor of Radiology ROLE OF MRI IN SCREENING, DIAGNOSIS AND MANAGEMENT OF BREAST CANCER B.Zandi Professor of Radiology Introduction In the USA, Breast Cancer is : The Most Common Non-Skin Cancer The Second Leading cause of

More information

Genomics in Public Health Vision and Goals for the Population Screening Working Group

Genomics in Public Health Vision and Goals for the Population Screening Working Group Genomics in Public Health Vision and Goals for the Population Screening Working Group Mike Murray Jim Evans Co-chairs; IOM Action Collaborative 24 February 2017 Washington DC Intent of IOM Action Collaborative

More information

HEREDITY & CANCER: Breast cancer as a model

HEREDITY & CANCER: Breast cancer as a model HEREDITY & CANCER: Breast cancer as a model Pierre O. Chappuis, MD Divisions of Oncology and Medical Genetics University Hospitals of Geneva, Switzerland Genetics, Cancer and Heredity Cancers are genetic

More information

Interpretation of p53 Immunostains. P53 Mutations are Ubiquitous in High Grade Serous Carcinoma. Diffuse strong positive nuclear staining

Interpretation of p53 Immunostains. P53 Mutations are Ubiquitous in High Grade Serous Carcinoma. Diffuse strong positive nuclear staining Stains for Tumor Classification p53 p16 WT1 HMGA2 P53 Mutations are Ubiquitous in High Grade Serous Carcinoma Source Ahmed et al Australian Ovarian Cancer Study Cancer Genome Atlas Research Network Cases

More information

NGS in tissue and liquid biopsy

NGS in tissue and liquid biopsy NGS in tissue and liquid biopsy Ana Vivancos, PhD Referencias So, why NGS in the clinics? 2000 Sanger Sequencing (1977-) 2016 NGS (2006-) ABIPrism (Applied Biosystems) Up to 2304 per day (96 sequences

More information

Germline Testing for Hereditary Cancer with Multigene Panel

Germline Testing for Hereditary Cancer with Multigene Panel Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with

More information

FAQ-Protocol 3. BRCA mutation carrier guidelines Frequently asked questions

FAQ-Protocol 3. BRCA mutation carrier guidelines Frequently asked questions ULast updated: 09/02/2015 Protocol 3 BRCA mutation carrier guidelines Frequently asked questions UQ: How accurate are the remaining lifetime and 5 year breast cancer risks in the table? These figures are

More information

Precision Medicine and Genetic Counseling : Is Yes always the correct answer?

Precision Medicine and Genetic Counseling : Is Yes always the correct answer? Precision Medicine and Genetic Counseling : Is Yes always the correct answer? Beverly M. Yashar, MS, PhD, CGC Director, Graduate Program in Genetic Counseling Professor, Department of Human Genetics. (yashar@umich.edu)

More information

MYOSIN BINDING PROTEIN C GENE (MYBPC3) MUTATIONS IN HYPERTROPHIC CARDIOMYOPATHY

MYOSIN BINDING PROTEIN C GENE (MYBPC3) MUTATIONS IN HYPERTROPHIC CARDIOMYOPATHY MYOSIN BINDING PROTEIN C GENE (MYBPC3) MUTATIONS IN HYPERTROPHIC CARDIOMYOPATHY Summary of the PhD Thesis Tímea Tóth Graduate School of Clinical Medicine University of Szeged Supervisor: Róbert Sepp, MD,

More information

Code CPT Descriptor Test Purpose and Method Crosswalk Recommendation SEPT9 (Septin9) (e.g., colorectal cancer) methylation analysis

Code CPT Descriptor Test Purpose and Method Crosswalk Recommendation SEPT9 (Septin9) (e.g., colorectal cancer) methylation analysis ASSOCIATION FOR MOLECULAR PATHOLOGY Education. Innovation & Improved Patient Care. Advocacy. 9650 Rockville Pike. Bethesda, Maryland 20814 Tel: 301-634-7939 Fax: 301-634-7995 amp@amp.org www.amp.org August

More information

CHR POS REF OBS ALLELE BUILD CLINICAL_SIGNIFICANCE

CHR POS REF OBS ALLELE BUILD CLINICAL_SIGNIFICANCE CHR POS REF OBS ALLELE BUILD CLINICAL_SIGNIFICANCE is_clinical dbsnp MITO GENE chr1 13273 G C heterozygous - - -. - DDX11L1 chr1 949654 A G Homozygous 52 - - rs8997 - ISG15 chr1 1021346 A G heterozygous

More information

p.arg119gly p.arg119his p.ala179thr c.540+1g>a c.617_633+6del Prediction basis structure

p.arg119gly p.arg119his p.ala179thr c.540+1g>a c.617_633+6del Prediction basis structure a Missense ATG p.arg119gly p.arg119his p.ala179thr p.ala189val p.gly206trp p.gly206arg p.arg251his p.ala257thr TGA 5 UTR 1 2 3 4 5 6 7 3 UTR Splice Site, Frameshift b Mutation p.gly206trp p.gly4fsx50 c.138+1g>a

More information

What s the Human Genome Project Got to Do with Developmental Disabilities?

What s the Human Genome Project Got to Do with Developmental Disabilities? What s the Human Genome Project Got to Do with Developmental Disabilities? Disclosures Neither speaker has anything to disclose. Phase Two: Interpretation Officially started in October 1990 Goals of the

More information

A guide to understanding variant classification

A guide to understanding variant classification White paper A guide to understanding variant classification In a diagnostic setting, variant classification forms the basis for clinical judgment, making proper classification of variants critical to your

More information

Analysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers

Analysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers Analysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers Gordon Blackshields Senior Bioinformatician Source BioScience 1 To Cancer Genetics Studies

More information

Exomes and Beyond Addressing the Genome with OneSeq. Madhuri Hegde, PhD, FACMG Emory University Emory Genetics Laboratory Atlanta, GA

Exomes and Beyond Addressing the Genome with OneSeq. Madhuri Hegde, PhD, FACMG Emory University Emory Genetics Laboratory Atlanta, GA Exomes and Beyond Addressing the Genome with OneSeq Madhuri Hegde, PhD, FACMG Emory University Emory Genetics Laboratory Atlanta, GA Technologies to Detect Various Types of Mutations RESOLUTION Targeted

More information

Do we all have an actionable genome?

Do we all have an actionable genome? Do we all have an actionable genome? Evidence from, and implications for, registries and electronic health records Professor Harry Hemingway, MD, FFPH, FRCP Director Farr Institute of Health Informatics

More information

Van test naar diagnose naar

Van test naar diagnose naar Van test naar diagnose naar V therapie op maat Marjolein Kriek, LUMC Joris Veltman, RUNMC Exome diagnostics in genetically heterogeneous disease Joris Veltman, PhD Department of Human Genetics Radboud

More information

Cancer Informatics Lecture

Cancer Informatics Lecture Cancer Informatics Lecture Mayo-UIUC Computational Genomics Course June 22, 2018 Krishna Rani Kalari Ph.D. Associate Professor 2017 MFMER 3702274-1 Outline The Cancer Genome Atlas (TCGA) Genomic Data Commons

More information

What can genetic studies tell us about ADHD? Dr Joanna Martin, Cardiff University

What can genetic studies tell us about ADHD? Dr Joanna Martin, Cardiff University What can genetic studies tell us about ADHD? Dr Joanna Martin, Cardiff University Outline of talk What do we know about causes of ADHD? Traditional family studies Modern molecular genetic studies How can

More information

Variant interpretation exercise. ACGS Somatic Variant Interpretation Workshop Joanne Mason 21/09/18

Variant interpretation exercise. ACGS Somatic Variant Interpretation Workshop Joanne Mason 21/09/18 Variant interpretation exercise ACGS Somatic Variant Interpretation Workshop Joanne Mason 21/09/18 Format of exercise Compile a list of tricky variants across solid cancer and haematological malignancy.

More information

Distal renal tubular acidosis: genetic and clinical spectrum

Distal renal tubular acidosis: genetic and clinical spectrum Distal renal tubular acidosis: genetic and clinical spectrum Sabrina Giglio Medical Genetics Unit, Meyer Children s University Hospital, University of Florence sabrina.giglio@meyer.it sabrinarita.giglio@unifi.it

More information

HA Convention 2010 Dr Liz YP Yuen Department of Chemical Pathology Prince of Wales Hospital

HA Convention 2010 Dr Liz YP Yuen Department of Chemical Pathology Prince of Wales Hospital HA Convention 2010 Dr Liz YP Yuen Department of Chemical Pathology Prince of Wales Hospital 1 2 Sudden death an unexpected natural death within a short time period, generally 1 hour or less from the onset

More information

UvA-DARE (Digital Academic Repository) Genetic basis of hypertrophic cardiomyopathy Bos, J.M. Link to publication

UvA-DARE (Digital Academic Repository) Genetic basis of hypertrophic cardiomyopathy Bos, J.M. Link to publication UvA-DARE (Digital Academic Repository) Genetic basis of hypertrophic cardiomyopathy Bos, J.M. Link to publication Citation for published version (APA): Bos, J. M. (2010). Genetic basis of hypertrophic

More information

PALB2 mutations in European familial pancreatic cancer families

PALB2 mutations in European familial pancreatic cancer families Clin Genet 2010: 78: 490 494 Printed in Singapore. All rights reserved Short Report 2010 John Wiley & Sons A/S CLINICAL GENETICS doi: 10.1111/j.1399-0004.2010.01425.x PALB2 mutations in European familial

More information

The lymphoma-associated NPM-ALK oncogene elicits a p16ink4a/prb-dependent tumor-suppressive pathway. Blood Jun 16;117(24):

The lymphoma-associated NPM-ALK oncogene elicits a p16ink4a/prb-dependent tumor-suppressive pathway. Blood Jun 16;117(24): DNA Sequencing Publications Standard Sequencing 1 Carro MS et al. DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle. 2006 Jun;5(11) 2 Lassandro L et al. The DNA sequence

More information

PALB2 c g>c is. VARIANT OF UNCERTAIN SIGNIFICANCE (VUS) CGI s summary of the available evidence is in Appendices A-C.

PALB2 c g>c is. VARIANT OF UNCERTAIN SIGNIFICANCE (VUS) CGI s summary of the available evidence is in Appendices A-C. Consultation sponsor (may not be the patient): First LastName [Patient identity withheld] Date received by CGI: 2 Sept 2017 Variant Fact Checker Report ID: 0000001.5 Date Variant Fact Checker issued: 12

More information

CDH1 truncating alterations were detected in all six plasmacytoid-variant bladder tumors analyzed by whole-exome sequencing.

CDH1 truncating alterations were detected in all six plasmacytoid-variant bladder tumors analyzed by whole-exome sequencing. Supplementary Figure 1 CDH1 truncating alterations were detected in all six plasmacytoid-variant bladder tumors analyzed by whole-exome sequencing. Whole-exome sequencing of six plasmacytoid-variant bladder

More information

Leveraging the Exome Sequencing Project: Creating a WHI Resource Through Exome Imputation in SHARe. Chris Carlson on behalf of WHISP May 5, 2011

Leveraging the Exome Sequencing Project: Creating a WHI Resource Through Exome Imputation in SHARe. Chris Carlson on behalf of WHISP May 5, 2011 Leveraging the Exome Sequencing Project: Creating a WHI Resource Through Exome Imputation in SHARe Chris Carlson on behalf of WHISP May 5, 2011 Exome Sequencing Project (ESP) Three cohort-based groups

More information

Informed Consent Columbia Whole Genome or Whole Exome Sequencing

Informed Consent Columbia Whole Genome or Whole Exome Sequencing Informed Consent Columbia Whole Genome or Whole Exome Sequencing Please read the following form carefully and discuss with your ordering physician before signing consent. This consent is intended for the

More information

Clinical Spectrum and Genetic Mechanism of GLUT1-DS. Yasushi ITO (Tokyo Women s Medical University, Japan)

Clinical Spectrum and Genetic Mechanism of GLUT1-DS. Yasushi ITO (Tokyo Women s Medical University, Japan) Clinical Spectrum and Genetic Mechanism of GLUT1-DS Yasushi ITO (Tokyo Women s Medical University, Japan) Glucose transporter type 1 (GLUT1) deficiency syndrome Mutation in the SLC2A1 / GLUT1 gene Deficiency

More information

The Focused Exome service at Bristol Genetics Laboratory

The Focused Exome service at Bristol Genetics Laboratory The Focused Exome service at Bristol Genetics Laboratory Chris Buxton Maggie Williams July 2016 Bristol Clinical exome Service to mid July Validation: Agilent FE kit, NextSeq 500 and new pipeline 1st reports

More information

Congenital Heart Disease How much of it is genetic?

Congenital Heart Disease How much of it is genetic? Congenital Heart Disease How much of it is genetic? Stephen Robertson Curekids Professor of Paediatric Genetics Dunedin School of Medicine University of Otago Congenital Heart Disease The most common survivable

More information

Clinical phenotypes associated with Desmosome gene mutations

Clinical phenotypes associated with Desmosome gene mutations Clinical phenotypes associated with Desmosome gene mutations Serio A, Serafini E, Pilotto A, Pasotti M, Gambarin F, Grasso M, Disabella E, Diegoli M, Tagliani M, Arbustini E Centre for Inherited Cardiovascular

More information

Frequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R

Frequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R Frequency(%) 1 a b ALK FS-indel ALK R1Q HRAS Q61R HRAS G13R IDH R17K IDH R14Q MET exon14 SS-indel KIT D8Y KIT L76P KIT exon11 NFS-indel SMAD4 R361 IDH1 R13 CTNNB1 S37 CTNNB1 S4 AKT1 E17K ERBB D769H ERBB

More information

Primary Care Approach to Genetic Cancer Syndromes

Primary Care Approach to Genetic Cancer Syndromes Primary Care Approach to Genetic Cancer Syndromes Jason M. Goldman, MD, FACP FAU School of Medicine Syndromes Hereditary Breast and Ovarian Cancer (HBOC) Hereditary Nonpolyposis Colorectal Cancer (HNPCC)

More information

Protein Domain-Centric Approach to Study Cancer Somatic Mutations from High-throughput Sequencing Studies

Protein Domain-Centric Approach to Study Cancer Somatic Mutations from High-throughput Sequencing Studies Protein Domain-Centric Approach to Study Cancer Somatic Mutations from High-throughput Sequencing Studies Dr. Maricel G. Kann Assistant Professor Dept of Biological Sciences UMBC 2 The term protein domain

More information

Genome Summary. Sequencing Coverage: Variation Counts: Known Phenotype Summary: 131 disease or trait variations are found in this genome

Genome Summary. Sequencing Coverage: Variation Counts: Known Phenotype Summary: 131 disease or trait variations are found in this genome Report Date: August 2, 215 Software Annotation Version: 8 Genome Summary Name: Greg Mendel Genome ID: genome_greg_mendel_dad Sequencing Provider: 23andMe Sequencing Type: Genotyping SNP Array Sequencing

More information

Genetics update and implications for (General) Practice

Genetics update and implications for (General) Practice Genetics update and implications for (General) Practice May 12 th 2018 Women s Health Symposium Clearwater Estate Dr Kate Gibson MB BCh, MRCP, FRACP Topics NZ Clinical Genetics delivery New Technologies

More information

CITATION FILE CONTENT/FORMAT

CITATION FILE CONTENT/FORMAT CITATION For any resultant publications using please cite: Matthew A. Field, Vicky Cho, T. Daniel Andrews, and Chris C. Goodnow (2015). "Reliably detecting clinically important variants requires both combined

More information

Familial and Hereditary Colon Cancer

Familial and Hereditary Colon Cancer Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of

More information

September 23, The Role of In Vitro Diagnostic Tests in Pediatric Master Protocol Development

September 23, The Role of In Vitro Diagnostic Tests in Pediatric Master Protocol Development The Role of In Vitro Diagnostic Tests in Pediatric Master Protocol Development September 23, 2016 Anand Pathak, MD, PhD, MPH Medical Officer Molecular Genetics Branch Division of Molecular Genetics and

More information

Deciphering Developmental Disorders (DDD) DDG2P

Deciphering Developmental Disorders (DDD) DDG2P Deciphering Developmental Disorders (DDD) DDG2P David FitzPatrick MRC Human Genetics Unit, University of Edinburgh Deciphering Developmental Disorders objectives research understand genetics of DD translation

More information

Sequencing studies implicate inherited mutations in autism

Sequencing studies implicate inherited mutations in autism NEWS Sequencing studies implicate inherited mutations in autism BY EMILY SINGER 23 JANUARY 2013 1 / 5 Unusual inheritance: Researchers have found a relatively mild mutation in a gene linked to Cohen syndrome,

More information

What we know about Li-Fraumeni syndrome

What we know about Li-Fraumeni syndrome What we know about Li-Fraumeni syndrome Dr Helen Hanson Consultant in Cancer Genetics St Georges Hospital, South-West Thames Regional Genetics Service History of LFS 1969 Li and Fraumeni describe four

More information

De novo mutational profile in RB1 clarified using a mutation rate modeling algorithm

De novo mutational profile in RB1 clarified using a mutation rate modeling algorithm Aggarwala et al. BMC Genomics (2017) 18:155 DOI 10.1186/s12864-017-3522-z RESEARCH ARTICLE Open Access De novo mutational profile in RB1 clarified using a mutation rate modeling algorithm Varun Aggarwala

More information